Literature DB >> 2184337

Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera.

U Wieland1, J E Kühn, C Jassoy, H Rübsamen-Waigmann, V Wolber, R W Braun.   

Abstract

The prevalence of antibodies against HIV-1 regulatory proteins in sera of HIV-infected patients from different stages of disease was investigated. HIV-1 vif, tat, and nef genes were cloned in procaryotic vectors and were expressed as MS-2 fusion proteins (vif and nef) or as a non-fusion protein (tat). These recombinant proteins were employed in immunoblot experiments. The specificity of the recognition was confirmed by competition experiments and with control sera from HIV-negative patients. Analysis of 136 serum samples revealed a high percentage of antibodies against nef, irrespective of the stage of disease. Antibodies against tat were found less frequently and increased from 16% to 40% with disease progression. Vif antibodies were detected only in a low percentage in early stages of disease, but their prevalence increased to 36% and 72% with progression of disease to AIDS-related complex and AIDS. Our data suggest that the detection of antibodies against nef may represent an additional and useful marker for the diagnosis of HIV infection, whereas the detection of vif antibodies may indicate disease progression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184337     DOI: 10.1007/bf00190145

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  29 in total

1.  An octamer of histones in chromatin and free in solution.

Authors:  J O Thomas; R D Kornberg
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma.

Authors:  D A McPhee; B E Kemp; S Cumming; D Stapleton; I D Gust; R R Doherty
Journal:  FEBS Lett       Date:  1988-06-20       Impact factor: 4.124

4.  Plasmid vectors for high-efficiency expression controlled by the PL promoter of coliphage lambda.

Authors:  E Remaut; P Stanssens; W Fiers
Journal:  Gene       Date:  1981-10       Impact factor: 3.688

5.  Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera.

Authors:  N C Kan; G Franchini; F Wong-Staal; G C DuBois; W G Robey; J A Lautenberger; T S Papas
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

6.  Reactivity of E. coli-derived trans-activating protein of human T lymphotropic virus type III with sera from patients with acquired immune deficiency syndrome.

Authors:  A D Barone; J J Silva; D D Ho; R C Gallo; F F Wong-Staal; N T Chang
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

7.  Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro.

Authors:  A Aldovini; C Debouck; M B Feinberg; M Rosenberg; S K Arya; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  Removal of N-linked carbohydrates decreases the infectivity of herpes simplex virus type 1.

Authors:  J E Kühn; B R Eing; R Brossmer; K Munk; R W Braun
Journal:  J Gen Virol       Date:  1988-11       Impact factor: 3.891

9.  Expression of diagnostic 31/32 kilodalton proteins of Schistosoma mansoni as fusions with bacteriophage MS2 polymerase.

Authors:  M Q Klinkert; A Ruppel; R Felleisen; G Link; E Beck
Journal:  Mol Biochem Parasitol       Date:  1988-01-15       Impact factor: 1.759

10.  Expression of p21 proteins in Escherichia coli and stereochemistry of the nucleotide-binding site.

Authors:  J Tucker; G Sczakiel; J Feuerstein; J John; R S Goody; A Wittinghofer
Journal:  EMBO J       Date:  1986-06       Impact factor: 11.598

View more
  12 in total

1.  In vitro cleavage of HIV-1 vif RNA by a synthetic ribozyme.

Authors:  E U Lorentzen; U Wieland; J E Kühn; R W Braun
Journal:  Virus Genes       Date:  1991-01       Impact factor: 2.332

Review 2.  Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Authors:  Giovanni Barillari; Barbara Ensoli
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

3.  Subcloning of HIV-2 nef genes in E. coli and immunological reactivity of expressed fusion proteins.

Authors:  R Ulrich; H Siakkou; J Mayer; N Kienzle; N Müller-Lantzsch; D H Krüger
Journal:  Virus Genes       Date:  1993-09       Impact factor: 2.332

4.  The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.

Authors:  G Barillari; R Gendelman; R C Gallo; B Ensoli
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

5.  Episodic occurrence of antibodies against the bovine leukemia virus Rex protein during the course of infection in sheep.

Authors:  M A Powers; D Grossman; L C Kidd; K Radke
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Serological markers as prognostic criteria for the course of HIV infection.

Authors:  A Kleinschmidt; A Matuschke; F D Goebel; V Erfle; R Hehlmann
Journal:  Infection       Date:  1991       Impact factor: 3.553

7.  Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Authors:  Lakshmi Ramakrishna; Krishnamurthy Kumar Anand; Kumarasamypet M Mohankumar; Udaykumar Ranga
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants.

Authors:  T R Reddy; G Kraus; O Yamada; D J Looney; M Suhasini; F Wong-Staal
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Novel mechanisms of central nervous system damage in HIV infection.

Authors:  Joy E Hazleton; Joan W Berman; Eliseo A Eugenin
Journal:  HIV AIDS (Auckl)       Date:  2010-03-11

10.  Characterization of Tat antibody responses in Chinese individuals infected with HIV-1.

Authors:  Qiuli Chen; Lan Li; Wenting Liao; Hongwei Zhang; Jinhong Wang; Bo Sheng; Huaqun Zhang; Xiaojie Huang; Yingying Ding; Tong Zhang; Jie Cao; Hao Wu; Wei Pan
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.